

Drug Policy

Policy:	200913	Initial Effective Date: 11/24/2009
Code(s):	J0717	Annual Review Date: 05/16/2024
SUBJECT:	Cimzia® (certolizumab pegol for subcutaneous [SC] injection [lyophilized] and SC injection [solution] – UCB)	Last Revised Date: 05/16/2024

Prior approval is required for some or all procedure codes listed in this Corporate Drug Policy.

Overview

Cimzia is a tumor necrosis factor (TNF) alpha blocker and is a recombinant humanized antibody Fab´ fragment (fragment antigen binding) that is a covalent conjugate to polyethylene glycol (PEG).¹ Pegylation delays the elimination of PEG polymers and the antibody, thus increasing the terminal elimination half-life of the Fab fragment. Unlike Remicade® (infliximab for intravenous [IV] infusion) and Humira® (adalimumab for SC injection), Cimzia does not contain an Fc portion of the antibody. Cimzia neutralizes the biological activity of TNF α and inhibits binding of TNF α with its receptors. TNF, a naturally occurring cytokine, mediates inflammation and modulates cellular immune responses. Increased levels of TNF have been implicated in the pathology of Crohn’s disease, psoriatic arthritis, and rheumatoid arthritis (RA). Increased levels of TNF are found in the synovial fluid of patients with RA and TNF has an important role in both the pathologic inflammation and the joint destruction that are characteristic of this disease. Increased levels of TNF are found in the bowel wall in areas involved by Crohn’s disease. After treatment with Cimzia, patients with Crohn’s disease have decreased levels of C-reactive protein (CRP).

Boxed Warnings

Cimzia has boxed warnings concerning risks of serious infection and the risk of malignancy.¹ Prior to initiating therapy with Cimzia, patients should be evaluated for active tuberculosis (TB) infection, and periodically during therapy patients should be assessed for latent TB infection. Patients should also be monitored for signs and symptoms of infection during and after treatment with Cimzia, and if a serious infection or sepsis develops, Cimzia should be discontinued. It is also recommended that patients treated with any TNF antagonist should be monitored for malignancies.

POLICY STATEMENT

This policy involves the use of Cimzia. Prior authorization is recommended for pharmacy and medical benefit coverage of Cimzia. Approval is recommended for those who meet the conditions of coverage in the **Criteria, Dosing (medical benefit requests only), Initial/Extended Approval, Duration of Therapy, and Labs/Diagnostics** for the diagnosis provided. **Waste Management** applies for all covered conditions that are administered by a healthcare professional. **Conditions Not Recommended for Approval** are listed following the recommended authorization criteria and Waste Management section. Requests for uses not listed in this policy will be reviewed for evidence of efficacy and for medical necessity on a case-by-case basis.

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. Always verify with the most current version at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> or <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

Drug Policy

Because of the specialized skills required for evaluation and diagnosis of patients treated with Cimzia as well as the monitoring required for AEs and long-term efficacy, initial approval requires Cimzia be prescribed by or in consultation with a physician who specializes in the condition being treated. All approvals for initial therapy are provided for the initial approval duration noted below; if reauthorization is allowed, a response to therapy is required for continuation of therapy unless otherwise noted below. **Cimzia is subject to the Inflammatory Conditions Care Value Program under pharmacy benefits.**

The site of care medical necessity criteria applies to initial therapy and reauthorizations under the medical benefit only.*

Recommended Authorization Criteria

Coverage of Cimzia is recommended in those who meet the following criteria:

Food and Drug Administration (FDA)-Approved Indications

1. Ankylosing Spondylitis (AS).

- a) **Initial Therapy.** Approve for 6 months if Cimzia is prescribed by or in consultation with a rheumatologist AND site of care medical necessity is met*.
- b) **Patients Currently Receiving Cimzia.** Approve for 1 year if the patient has had a response (e.g., decreased pain or stiffness, improved function or activities of daily living), as determined by the prescriber. The patient may not have a full response, but there should have been a recent or past response to Cimzia. Site of care medical necessity must be met*

Dosing in Ankylosing Spondylitis. The recommended dose of Cimzia for adult patients with ankylosing spondylitis is 400 mg (given as 2 subcutaneous injections of 200 mg each) initially and at weeks 2 and 4, followed by 200 mg every 2 weeks or 400 mg every 4 weeks.¹

2. Crohn's Disease in an Adult.

 Approve if the patient meets the following criteria¹:

- a) **Initial Therapy.** Approve for 6 months if the patient meets the following criteria (i, ii, and iii)¹:
 - i. Patient is ≥ 18 years of age; AND
 - ii. The patient meets one of the following conditions (1, 2, 3, or 4):
 - 1) The patient has tried or is currently taking corticosteroids, or corticosteroids are contraindicated in this patient; OR
 - 2) The patient has tried one other conventional systemic agent for Crohn's disease; OR
Note: Examples of systemic therapies for Crohn's disease include azathioprine, 6-mercaptopurine, and methotrexate. A previous trial of a biologic also counts as a trial of one other agent for Crohn's disease. Refer to Appendix A for examples of biologics used for Crohn's disease. A trial of mesalamine does not count as a systemic agent for Crohn's disease.
 - 3) Patient has enterocutaneous (perianal or abdominal) or rectovaginal fistulas; OR
 - 4) Patient had ileocolonic resection (to reduce the chance of Crohn's disease recurrence); AND
 - iii. Cimzia is prescribed by or in consultation with a gastroenterologist; AND
 - iv. Site of care medical necessity is met*.

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. Always verify with the most current version at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> or <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

Drug Policy

- b) **Patients Currently Receiving Cimzia.** Approve for 1 year if the patient has had a response, as determined by the prescriber. The patient may not have a full response, but there should have been a recent or past response to Cimzia. Site of care medical necessity must be met*.

Note: Patients with fistulizing Crohn's disease or Crohn's disease of the ileal pouch must meet the above criteria for Crohn's disease in adults.

Cimzia is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adults with moderately to severely active disease who have had an inadequate response to conventional therapy.¹

Dosing in Crohn's Disease. The recommended initial adult dose of Cimzia is 400 mg (given as two subcutaneous injections of 200 mg) initially, and at Weeks 2 and 4. In patients who obtain a clinical response, the recommended maintenance regimen is 400 mg every four weeks.¹

3. Psoriatic Arthritis (PsA).

- a) **Initial Therapy.** Approve for 6 months if Cimzia is prescribed by or in consultation with a rheumatologist or a dermatologist AND site of care medical necessity is met*.
- b) **Patients Currently Receiving Cimzia.** Approve for 1 year if the patient has had a response (e.g., less joint pain, morning stiffness, or fatigue; improved function or activities of daily living; decreased soft tissue swelling in joints or tendon sheaths; improvements in acute phase reactants [for example, CRP]), as determined by the prescriber. The patient may not have a full response, but there should have been a recent or past response to Cimzia. Site of care medical necessity must be met*.

Cimzia is indicated for PsA and can be used alone or in combination with DMARDs.¹ In the pivotal trial, Cimzia was effective in patients with active PsA despite therapy with a DMARD; approximately 20% of patients had previously tried a TNF blocker (note: primary failures were excluded).^{1,7} There are few well-controlled, prospective studies with adequate duration that have evaluated the efficacy of the oral DMARDs.¹³ According to the EULAR recommendations for treatment of PsA (2012), NSAIDs are recommended as first-line treatment.¹⁴ Recommendations for other therapies before receiving a TNF blocker vary according to the manifestations of the disease, prognostic factors, and efficacy/toxicity of previous therapies. The TNF inhibitors indicated in PsA are equally effective for treatment of PsA, inhibition of radiographic progression, and improving physical function in patients with PsA. The traditional DMARDs have not been shown to prevent the progression of radiographic (structural) damage or to have significant impact on axial disease, dactylitis, or enthesitis in PsA.¹⁴⁻¹⁵ This is in contrast with the newer biological DMARDs which have shown efficacy in well-controlled trials in reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with PsA.^{1,7-8,14}

Dosing in Psoriatic Arthritis. The recommended dose of Cimzia for adult patients with psoriatic arthritis is 400 mg (given as 2 subcutaneous injections of 200 mg each) initially and at week 2 and 4, followed by 200 mg every other week. For maintenance dosing, Cimzia 400 mg every 4 weeks can be considered.¹

4. Rheumatoid Arthritis (RA) in an Adult

- a) **Initial Therapy.** Approve for 6 months if the patient meets the following criteria (A, B, and C):¹⁶

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. Always verify with the most current version at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> or <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

Drug Policy

- A. The patient meets one of the following conditions (i, ii or iii):
 - i. The patient meets one of the criteria below:
 - a. The patient has tried ONE conventional synthetic disease-modifying antirheumatic drug (DMARD) for at least 3 months (e.g., methotrexate [oral or injectable], leflunomide, hydroxychloroquine, and sulfasalazine)
 - b. The patient has tried ONE biologic for at least 3 months disease-modifying antirheumatic drug (DMARD) [Refer to Appendix A for examples]; OR
 - B. Cimzia is prescribed by or in consultation with a rheumatologist AND
 - C. Site of care medical necessity is met*.
- b) Patients Currently Receiving Cimzia. Approve for 1 year if the patient has had a response (e.g., less joint pain, morning stiffness, or fatigue; improved function or activities of daily living; decreased soft tissue swelling in joints or tendon sheaths; improved laboratory values; reduced dosage of corticosteroids), as determined by the prescriber. The patient may not have a full response, but there should have been a recent or past response to Cimzia. Site of care medical necessity must be met*.

Cimzia is indicated for moderate or severe active RA in adults and can be used alone or in combination with MTX or other non-biologic DMARDs.¹ Most patients will have received initial therapy with an oral DMARD(s) (e.g., hydroxychloroquine, leflunomide, sulfasalazine, MTX) or combination DMARD therapy (including double or triple therapy).¹⁶ However, current recommendations from the American College of Rheumatology (ACR) [2012] note that patients with early RA (defined as disease duration < 6 months) with important markers of poor prognosis may be started early on a biologic agent, either alone or in combination with MTX. The criteria for patients with contraindications or intolerance to DMARDs are recommended based on the professional opinion of specialized physicians.

Dosing in Rheumatoid Arthritis. The recommended dose of Cimzia for adult patients with rheumatoid arthritis is 400 mg (given as two subcutaneous injections of 200 mg) initially and at Weeks 2 and 4, followed by 200 mg every other week. For maintenance dosing, Cimzia 400 mg every 4 weeks can be considered.

- 5. **Moderate to Severe Plaque Psoriasis.** Approve for the duration noted if the patient meets ONE of the following (A or B):
 - A. Initial Therapy. Approve for 3 months if the patient meets the following criteria (i, ii, iii and iv):
 - i. The patient is 18 years of age or older; AND
 - ii. Cimzia is prescribed by or in consultation with a dermatologist; AND
 - iii. Site of care medical necessity is met.*
 - iv. The patient meets one of the following criteria below (a or b):
 - a. The patient has tried at least one traditional systemic agent for psoriasis (e.g. methotrexate [MTX], cyclosporine, acitretin tablets, or psoralen plus ultraviolet A light [PUVA]) for at least 3 months, unless intolerant; OR
 - b. The patient has a contraindication to methotrexate, as determined by the prescriber

Drug Policy

- B. Patients Currently Receiving Cimzia.** Approve for 1 year if the patient has had a response, as determined by the prescriber. The patient may not have a full response, but there should have been a recent or past response to Cimzia and site of care medical necessity is met.*

Dosing in Plaque psoriasis: SubQ: 400 mg every other week. Note: For patients ≤ 90 kg, an initial dose of 400 mg at weeks 0, 2, and 4 followed by 200 mg every other week thereafter may be considered.

6. Non-radiographic Axial Spondyloarthritis (SpA).

- A) **Initial Therapy.** Approve for 6 months if the patient meets the following criteria (i OR ii AND iii AND iv):
- C-reactive protein (CRP) elevated beyond the upper limit of normal for the reporting laboratory; OR
 - Sacroiliitis reported on magnetic resonance imaging (MRI); AND
 - Cimzia is prescribed by or in consultation with a rheumatologist; AND
 - Site of care medical necessity must be met*.
- B) **Patients Currently Receiving Cimzia.** Approve for 1 year if the patient has had a response (e.g., less joint pain, morning stiffness, or fatigue; improved function or activities of daily living; decreased soft tissue swelling in joints or tendon sheaths; improved laboratory values; reduced dosage of corticosteroids), as determined by the prescriber. The patient may not have a full response, but there should have been a recent or past response to Cimzia. Site of care medical necessity must be met*.

Dosing in Non-radiographic Axial Spondyloarthritis: SubQ: 400 mg initially and at weeks 2 and 4, followed by 200 mg every 2 weeks or 400 mg every 4 weeks.

Other Uses with Supportive Evidence

7. Spondyloarthritis (SpA), Subtypes Other than Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis or Psoriatic Arthritis (e.g., undifferentiated arthritis, Reactive Arthritis [Reiter's disease]) [NOTE: For AS or PsA, refer to the respective criteria under FDA-approved indications].

- A) **Initial Therapy.** Approve for 6 months if the patient meets the following criteria (i or ii, iii, and iv):
- The patient has arthritis primarily in the knees, ankles, elbows, wrists, hands, and/or feet AND has tried at least ONE conventional synthetic DMARD (e.g., methotrexate [MTX], leflunomide, sulfasalazine); OR
 - Patient has tried at least ONE conventional synthetic disease-modifying antirheumatic drug (DMARD); AND
 - Cimzia is prescribed by or in consultation with a rheumatologist; AND
 - Site of care medical necessity must be met*.
- B) **Patients Currently Receiving Cimzia.** Approve for 1 year if the patient has been established on the requested drug for at least 6 months; AND when assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating the requested drug); OR compared with baseline (prior to initiating the requested drug), patient experienced an improvement in at least one symptom, such as decreased pain or stiffness, or improvement in function or activities of daily living. Site of care medical necessity must be met*. Note: A patient who has received < 6 months of therapy or who is restarting therapy with the requested drug is reviewed under criterion A (Initial Therapy)

Drug Policy

Dosing in Ankylosing spondylitis: SubQ: Initial: 400 mg, repeat dose 2 and 4 weeks after initial dose;
Maintenance: 200 mg every 2 weeks or 400 mg every 4 weeks

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Cimzia is recommended in circumstances that are listed in the Recommended Authorization Criteria (FDA-approved indications and Other Uses with Supportive Evidence). The following provides rationale for specific Exclusions. This is not an exhaustive list of Exclusions.

- 1. Concurrent Use with a Biologic DMARD or Targeted Synthetic DMARD.** Cimzia should not be administered in combination with another biologic agent for an inflammatory condition (Refer to Appendix A for examples). Combination therapy with two biologic agents is not recommended due to a higher rate of adverse effects with combinations and lack of additive efficacy.¹⁷ Xeljanz® [tofacitinib] should not be used in combination with biologic DMARDs such as Remicade.¹⁸ Targeted synthetic DMARDs (e.g., Xeljanz, Otezla® [apremilast]) do not have data supporting use in combination with biologic DMARDs. Due to similar safety concerns (i.e., increased risk of AEs) plus lack of evidence for additive efficacy, targeted synthetic DMARDs should not be used in combination with biologic DMARDs such as Cimzia. **Note:** This does NOT exclude the use of conventional synthetic DMARDs (e.g., MTX, leflunomide, hydroxychloroquine, and sulfasalazine) in combination with Cimzia.
- 2. Concurrent use with Otezla.** No evidence to suggest combination therapy with Otezla offers additional therapeutic benefit.
- 3.** Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

Documentation Requirements:

The Company reserves the right to request additional documentation as part of its coverage determination process. The Company may deny reimbursement when it has determined that the drug provided or services performed were not medically necessary, investigational or experimental, not within the scope of benefits afforded to the member and/or a pattern of billing or other practice has been found to be either inappropriate or excessive. Additional documentation supporting medical necessity for the services provided must be made available upon request to the Company. Documentation requested may include patient records, test results and/or credentials of the provider ordering or performing a service. The Company also reserves the right to modify, revise, change, apply and interpret this policy at its sole discretion, and the exercise of this discretion shall be final and binding.

REFERENCES

- Cimzia® for injection [prescribing information]. Smyrna, GA: UCB, Inc.; Sep 2019.
- Sandborn WJ, Feagan BG, Stoinov S, et al; PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. *N Engl J Med.* 2007;357:228-238.
- Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al; PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. *N Engl J Med.* 2007;357:239-250.

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. Always verify with the most current version at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> or <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

Drug Policy

- Keystone E, van der Heijde D, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Arthritis Rheum.* 2008;58:3319-3329.
- Smolen J, Landewé RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: The RAPID 2 study. *Ann Rheum Dis.* 2009;68:797-804.
- Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. *Ann Rheum Dis.* 2009;68:805-811.
- Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). *Ann Rheum Dis.* 2013 Aug 28. [Epub ahead of print].
- van der Heijde D, Fleischmann R, Wollenhaupt J, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. *Ann Rheum Dis.* 2013 Aug 28. [Epub ahead of print].
- Landewé R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. *Ann Rheum Dis.* 2013 Sep 6. [Epub ahead of print].
- Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Ann Rheum Dis.* 2011;70(6):896-904.
- van den Berg R, Baraliakos X, Braun J, van der Heijde D. First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. *Rheumatology (Oxford).* 2012;51(8):1388-1396.
- Zochling J, Braun J. Quality indicators, guidelines and outcome measures in ankylosing spondylitis. *Clin Exp Rheumatol.* 2007;25(6 Suppl 47):147-152.
- Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. *Ann Rheum Dis.* 2012;71(3):319-326.
- Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. *Ann Rheum Dis.* 2012;71(1):4-12.
- Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. *Ann Rheum Dis.* 2009;68:1387-1394.
- Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. *Arthritis Care Res (Hoboken).* 2012;64(5):625-639.
- Furst DE, Keystone EC, So AK, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. *Ann Rheum Dis.* 2013;72 Suppl 2:ii2-34.
- Xeljanz® tablets [prescribing information]. New York, NY: Pfizer Inc; November 2012.
- Reich K, Ortonne JP, Gottlieb AB, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. *Br J Dermatol.* 2012;167(1):180-190.
- **Other References Utilized**
- Keystone EC, Combe B, Smolen J, et al. Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. *Rheumatology (Oxford).* 2012;51(9):1628-1638.
- Lichtenstein GR, Thomsen OO, Schreiber S, et al. Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months. *Clin Gastroenterol Hepatol.* 2010;8(7):600-609.
- Sandborn WJ, Abreu MT, D'Haens G, et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. *Clin Gastroenterol Hepatol.* 2010;8(8):688-695.
- Sandborn WJ, Schreiber S, Hanauer SB, et al; PRECiSE 4 Study Investigators. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. *Clin Gastroenterol Hepatol.* 2010;8(8):696-702.
- Schreiber S, Colombel JF, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. *Am J Gastroenterol.* 2010;105(7):1574-1782.
- Schreiber S, Lawrance IC, Thomsen OØ, et al. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. *Aliment Pharmacol Ther.* 2011;33(2):185-193.

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. Always verify with the most current version at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> or <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

Drug Policy

- Landewé R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. *Ann Rheum Dis.* 2014;73(1):39-47

FOR MEDICAL BENEFIT COVERAGE REQUESTS:

*MMO Site of Care Medical Necessity Criteria:

- Medications in this policy will be administered in a place of service that is a non-hospital facility based location (i.e., home infusion provider, provider's office, free-standing ambulatory infusion center) unless *at least one* of the following are met[†]:
 1. Age less than 18* years; or
 2. Clinically unstable based upon documented medical history (e.g., patient is hemodynamically unstable); or
 3. History of a severe adverse event from previous administration of the prescribed medication; or
 4. Requested medication is being administered as follows:
 - part of a chemotherapy regimen (e.g., anti-neoplastic agent, colony stimulating factor, erythropoiesis-stimulating agent, anti-emetic) for treatment of cancer; or
 - administered with dialysis; or
 5. Physical or cognitive impairment and caregiver is not available to assist with safe administration of prescribed medication in the home; or
 6. Experiencing adverse events that are not managed by premedication or resources available at a non-hospital facility based location.

No initial doses are allowed in a hospital based outpatient facility without other above criteria being met.

* Effective 01/01/2019, age criterion applies to 18 years of older. Age at original effective date (03/01/2016) was 21 years or older.

[†]This criterion does not apply to Medicare or Medicare Advantage members.

Drug Policy

Prior approval is required for HCPCS Codes J0717

Edits and Denials:

Prior approval: Prior approval is required for Cimzia (**HCPCS Code J0717**). Requests for prior approval will be authorized by a nurse reviewer if submitted documentation meets criteria outlined within the Corporate Medical Policy.

Requests for prior approval will be forwarded to a qualified physician reviewer if submitted documentation does not meet criteria outlined within Corporate Medical Policy.

TOPPS: Claims received with **HCPCS Code J0717** will pend with **Remark Code M3M or M4M** and will be adjudicated in accordance with the Corporate Medical Policy.

Liability: A participating provider will be required to write off charges denied as not medically necessary.

HCPCS Code(s):	
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)

Appendix A

	Mechanism of Action	Examples of Inflammatory Indications*
Biologics		
Adalimumab SC Products (Humira®, biosimilars)	Inhibition of TNF	AS, CD, JIA, PsO, PsA, RA, UC
Cimzia® (certolizumab pegol SC injection)	Inhibition of TNF	AS, CD, nr-axSpA, PsO, PsA, RA
Etanercept SC Products (Enbrel®, biosimilars)	Inhibition of TNF	AS, JIA, PsO, PsA
Zymfentra® (infliximab-dyyb SC injection)	Inhibition of TNF	CD, UC
Infliximab IV Products (Remicade®, biosimilars)	Inhibition of TNF	AS, CD, PsO, PsA, RA, UC
Simponi®, Simponi® Aria™ (golimumab SC injection, golimumab IV infusion)	Inhibition of TNF	SC formulation: AS, PsA, RA, UC IV formulation: AS, PJIA, PsA, RA
Actemra® (tocilizumab IV infusion, tocilizumab SC injection)	Inhibition of IL-6	SC formulation: PJIA, RA, SJIA IV formulation: PJIA, RA, SJIA
Kezvara® (sarilumab SC injection)	Inhibition of IL-6	RA, PMR
Orencia® (abatacept IV infusion, abatacept SC injection)	T-cell costimulation modulator	SC formulation: JIA, PSA, RA IV formulation: JIA, PsA, RA
Rituximab IV Products (Rituxan®, biosimilars)	CD20-directed cytolytic antibody	RA
Kineret® (anakinra SC injection)	Inhibition of IL-1	JIA [^] , RA
Stelara® (ustekinumab SC injection, ustekinumab IV infusion)	Inhibition of IL-12/23	SC formulation: CD, PsO, PsA, UC IV formulation: CD, UC

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. Always verify with the most current version at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> or <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

Drug Policy

Siliq™ (brodalumab SC injection)	Inhibition of IL-17RA	PsO
Bimzelx® (bimekizumab-bkzx SC injection)	Inhibition of IL-17A and IL-17F	PsO
Cosentyx® (secukinumab SC injection, secukinumab IV infusion)	Inhibition of IL-17A	SC formulation: AS, ERA, nr-axSpA, PsO, PsA IV formulation: AS, nr-axSpA, PsA
Taltz® (ixekizumab SC injection)	Inhibition of IL-17A	AS, nr-axSpA, PsO, PsA
Ilumya™ (tildrakizumab-asnm SC injection)	Inhibition of IL-23	PsO
Omvoh® (mirikizumab-mrkz SC injection, mirikizumab-mrkz IV infusion)	Inhibition of IL-23	UC
Skyrizi® (risankizumab-rzaa SC injection, risankizumab-rzaa IV infusion)	Inhibition of IL-23	SC formulation: CD, PSA, PsO IV formulation: CD
Tremfya™ (guselkumab SC injection)	Inhibition of IL-23	PsO
Entyvio™ (vedolizumab IV infusion, vedolizimab SC injection)	Integrin receptor antagonist	SC formulation: UC IV formulation: CD, UC
Oral Therapies/Targeted Synthetic DMARDs		
Otezla® (apremilast tablets)	Inhibition of PDE4	PsO, PsA
Cibinqo™ (abrocitinib tablets)	Inhibition of JAK pathways	AD
Olumiant® (baricitinib tablets)	Inhibition of JAK pathways	RA
Rinvoq® (upadacitinib extended-release tablets)	Inhibition of JAK pathways	AD, AS, nr-axSpA, RA, PsA, UC
Sotyktu™ (deucravacitinib tablets)	Inhibition of TYK2	PsO
Xeljanz® (tofacitinib tablets)	Inhibition of JAK pathways	RA, PJA, PsA, UC
Xeljanz® XR (tofacitinib extended-release tablets)	Inhibition of JAK pathways	RA, PsA, UC
Velsipity® (etrasimod tablets)	Sphingosine 1 phosphate receptor modulator	UC
Zeposia® (ozanimod tablets)	Sphingosine 1 phosphate receptor modulator	UC

* Not an all-inclusive list of indications (e.g., oncology indications and rare inflammatory conditions are not listed). Refer to the prescribing information for the respective agent for FDA-approved indications; SC – Subcutaneous; TNF – Tumor necrosis factor; AS – Ankylosing spondylitis; CD – Crohn’s disease; JIA – Juvenile idiopathic arthritis; PsO – Plaque psoriasis; PsA – Psoriatic arthritis; RA – Rheumatoid arthritis; UC – Ulcerative colitis; nr-axSpA – Non-radiographic axial spondyloarthritis; IV – Intravenous, PJA – Polyarticular juvenile idiopathic arthritis; IL – Interleukin; SJA – Systemic juvenile idiopathic arthritis; PMR – Polymyalgia rheumatic; ^ Off-label use of Kineret in JIA supported in guidelines; ERA – Entesitis-related arthritis; DMARD – Disease-modifying antirheumatic drug; PDE4 – Phosphodiesterase 4; JAK – Janus kinase; AD – Atopic dermatitis; TYK2 – Tyrosine kinase 2.